Skip to content

The Effects of Cognitive-motor Dual-task Intervention on Fall Prevention Among Older Adults

The Effects and Mechanisms of Game-based Cognitive-motor Dual-task Intervention on Fall Prevention Among Older Adults

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07025278
Enrollment
125
Registered
2025-06-17
Start date
2027-03-31
Completion date
2027-03-31
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive-motor Dual-task, ELDERLY PEOPLE, Fall Prevention, Intervention

Brief summary

1. Develop an evidence-based dual-task intervention programme incorporating gamification for fall risk reduction in older adults. 2. Examine the effects of the gamified dual-task intervention on fall risk in older adults. 3. Elucidate the underlying mechanisms of the optimal gamified dual-task intervention programme in reducing falls in older adults.

Interventions

BEHAVIORALMedium difficulty fixed priority group

During the intervention process, participants carried out cognitive and motor tasks simultaneously. They were told to divide attention equally between them and not prioritize one over the other.

BEHAVIORALMedium difficulty variable priority group

During the intervention process, participants performed medium-difficulty cognitive and motor tasks simultaneously. Participants alter focus between the motor task and the cognitive task every half of the intervention time.

Sponsors

Jinyao Wang
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Given the inherent nature of the intervention, blinding of participants and intervention providers was not feasible; only the outcome assessors were kept blinded to group assignment.

Intervention model description

A Sequential Multiple Assignment Randomized Trial (SMART) design was adopted in this study. The SMART intervention consisted of two stages. In the first stage, participants were randomly assigned to either the VP group (receiving variable-priority dual-task intervention) or the FP group (receiving fixed-priority dual-task intervention). Outcome data were collected and assessed immediately after the first-stage intervention, and participants were classified as responders or non-responders based on predefined tailoring variables. Responders in both the VP and FP groups continued with their original intervention protocol in the second stage, whereas non-responders were re-randomized in the second stage. The re-randomization was conducted within their original priority group by adjusting the difficulty level of the intervention, with non-responders being re-assigned to either a difficulty-increase or difficulty-decrease CMDT intervention group.

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Age ≥ 65 years old; 2. Able to walk independently for at least 10 meters without obvious pain or difficulty; 3. Free from lower limb and foot deformities, wounds, ulcers, or other diseases, and capable of wearing flexible devices; 4. Scored as low or moderate fall risk on the Morse Fall Risk Assessment Scale; 5. Scored \> 40 points on the Berg Balance Scale and \< 20 seconds on the Time Up and Go Test (TUG); 6. Scored ≥ 21 points on the Mini-Mental State Examination (MMSE); 7. With an educational level of primary school or above, able to correctly understand instructions and make corresponding responses; 8. Without diseases that severely affect cognitive and motor functions, including cardiovascular diseases (such as uncontrolled hypertension, heart failure, etc.), neurological diseases (such as Parkinson's disease, stroke, epilepsy, etc.), musculoskeletal diseases (such as severe arthritis, recent fractures, etc.), etc.; 9. Normal vision and hearing or corrected to normal, without affecting the understanding of instructions and participation in interventions; 10. Conscious and able to understand the test requirements; 11. Able to understand and sign the informed consent form voluntarily, and willing to cooperate in completing the research procedures.

Exclusion criteria

1. Must rely on assistive walking devices or others to walk; 2. Individuals with color vision disorders, including various types of color blindness and color weakness; 3. Unable to correctly perform addition and subtraction operations; 4. Those allergic to the materials of research equipment; 5. Currently participating in other research or intervention projects that may affect the effectiveness of this intervention.

Design outcomes

Primary

MeasureTime frame
The changes of Time up and go test from baseline to the end of the interventionFrom enrollment to the end of the intervention at 3 weeks

Secondary

MeasureTime frameDescription
The changes of the Berg Balance Scale (BBS) from baseline to the end of the interventionFrom enrollment to the end of the intervention at 3 weeksThe minimum and maximum values of the Berg Balance Scale are 0 and 56 points, respectively. The higher the score, the better the balance ability, and the lower the risk of falling.
The changes of the Mini-Mental State Examination (MMSE) from baseline to the end of the interventionFrom enrollment to the end of the intervention at 3 weeksThe minimum and maximum values of the Mini-Mental State Examination (MMSE) are 0 and 30 points, respectively. The higher the score, the better the cognitive function.
The changes of Trail making test from baseline to the end of the interventionFrom enrollment to the end of the intervention at 3 weeks
The changes of gait from baseline to the end of the interventionFrom enrollment to the end of the intervention at 3 weeksThe gait of participants is measured using insole plantar pressure measurement systems to assess the step length, cadence, walking speed, and plantar pressure distribution. The results could determine whether gait abnormalities are present.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 30, 2026